All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2019; the latest 2025-11-12.
From the record
Arcturus Therapeutics Holdings Inc.'s filings since 2019 show 3 warning events of 2 kinds: an auditor change (8-K item 4.01, the latest 2024-04-05); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2025-11-12) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+26.6% a year over 8 filed years; profitable in 1 of 8.
From the record
Arcturus Therapeutics Holdings Inc.'s 8 filed years say what it did: revenue went from $16 million in fiscal 2018 to $82 million in fiscal 2025, up 26.6% a year; it rose in 3 of 7 years; the deepest fall was 60% from fiscal 2022 to fiscal 2025; net income was positive in 1 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Arcturus Therapeutics Holdings Inc.'s shareholder treatment is put at 8.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 13% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -31%: lost 31¢ per shareholder dollar. Leverage 21%: owes 21¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Arcturus Therapeutics Holdings Inc. lost about 31 cents for every dollar of shareholders' money. Leverage: it owed about 21 cents per dollar of assets, and net share issuance: its share count grew 1.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 46% of 315 in its family; net margin -80.2%.
From the record
Arcturus Therapeutics Holdings Inc.'s standing among 315 graded names in its industry family: revenue of $82 million in fiscal 2025 ranks in the top 36% by size; a net margin of -80.2% ranks in the top 45%; revenue growth of -26.4% a year over the last 3 filed years ranks in the bottom 19% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 33% of 315 in its family for leadership; chief executive since 2019.
From the record
Arcturus Therapeutics Holdings Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Payne, Joseph E (President and CEO, as filed), filing under that title since 2019-08-30, 7.2 years (top 28% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 6.7 years (top 30%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 36% of 273 in its family for room to expand.
From the record
Arcturus Therapeutics Holdings Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $233 million against no long-term debt tagged leaves 85.9% of its assets as net cash, top 14% of its family; cash from operations less capital spending is -90.8% of revenue (top 49%); research spending of 136.8% of revenue (top 46%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 17% of 306 in its family for growth drivers.
From the record
Arcturus Therapeutics Holdings Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -26.4% a year over the last three filed years against 26.6% over all 8, slowing (bottom 13% of its family); the newest year grew -46.2% (bottom 17%); research spending grew -8.8% a year (bottom 33%); capital spending grew -69% a year (bottom 7%) (its annual reports). Arcturus Therapeutics Holdings Inc. reported 2 product lines in fiscal 2025: Collaboration Revenue at $67 million (82%), Grant at $15 million (18%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 20% of 233 in its family for expectations against reality.
From the record
Arcturus Therapeutics Holdings Inc.'s newest year against its own record: revenue of $82 million in fiscal 2025 came in 37.4% below the $131 million its prior three years' pace pointed to (bottom 24% of its family); net income of $66 million against a prior three-year average of $34 million (bottom 15%); a net margin of -80.2% against -22.1% before (bottom 21%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made